NCT03378401已完成3 期
Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 114
- 试验地点
- 3
- 主要终点
- Total mean PI (Plaque index according to Silness and Löe) after 5 days of treatment at Visit 2
研究概览
简要总结
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation. The study will consist of a 14-day screening period and a 5-day treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult male and female subjects (aged 18 and older);
- •Subjects with a total mean gingival index1 (GI, Löe, 1967) ≤1.5 (0.0-1.5);
- •Subjects with at least 20 teeth (excluding wisdom teeth) with complete natural "Ramfjord-teeth" or their replacement teeth and 10 natural anterior teeth (excluding teeth provided with prosthetics such as crowns, dental bridges, veneers or large vestibular fillings such as large cervical or frontal teeth fillings; teeth with small interdental and orally oriented fillings are allowed);
- •Non-pigmented gingiva;
- •Signed informed consent.
排除标准
- •Subjects with severe systemic diseases (e.g. hepatitis, human immunodeficiency virus [HIV] infection, tuberculosis, acute cancer treatment);
- •Subjects who require endocarditis prophylaxis for dental examination and treatment;
- •Subjects with caries requiring treatment (e.g. caries with cavity) or other oral diseases (including gingival hyperplasia, diseases of the oral mucosa);
- •Subjects who have a history of chronic or aggressive periodontitis;
- •Subjects with current moderate or severe chronic or aggressive periodontitis (periodontal screening index [PSI] >2 in more than 2 sextants or PSI >3);
- •Subjects showing a GI score of 3 on at least one tooth;
- •Subjects who underwent oral surgery within 14 days prior to Screening;
- •Subjects who used antiseptic mouth rinse within 14 days prior to Screening;
- •Subjects wearing orthodontic appliances and removable dentures (Wire-retainers after orthodontic treatment are allowed);
- •Subjects treated with antibiotics less than 3 months prior to the baseline examination at Visit 1 and/or planning such treatment for the duration of the study;
- •Subjects treated with systemically acting corticosteroids or corticosteroids applied via the oral cavity (e.g. asthma sprays);
- •Subjects who suffer from xerostomia;
- •Subjects who have a known hypersensitivity or allergy to the test product and its ingredients or to medications that have a similar chemical structure;
- •Participation of the subject in another clinical study within the last 4 weeks before enrolment in and during this study;
- •Incapability of assessing essence and possible consequences of the study (e.g. alcoholism);
- •Pregnant or breastfeeding women;
- •Women with childbearing potential except those who fulfill one of the following criteria:
- •Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum follicle-stimulating hormone [FSH] >40 U/ml);
- •Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy);
- •Continuous and correct application of a highly effective contraception method with a Pearl Index <1% (e.g. implants, depots, oral contraceptives, intrauterine device [IUD]);
- •Sexual abstinence; whereas sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject;
- •Confirmation of vasectomy of the sexual partner;
- •Evidence suggesting that the subject is not likely to follow the study protocol (e.g. lacking compliance).
研究组 & 干预措施
Octenidine Mouthwash
Experimental
0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
干预措施: Octenidinedihydrochlorid (Drug)
Placebo
Placebo Comparator
Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
干预措施: Placebo (Other)
结局指标
主要结局
Total mean PI (Plaque index according to Silness and Löe) after 5 days of treatment at Visit 2
时间窗: after 5 days of treatment
The total mean PI is the sum of the individual scores divided by the number of investigated sites.
次要结局
- Bacterial count reduction in saliva after a single administration of OML vs placebo(after 1 minute of rinsing)
- Change in total mean GI (Gingival Index according to Löe, 1967) from Visit 1 to Visit 2(baseline and after 5 days of treatment)
- Incidence and severity of AEs (adverse events)(5 days)
- Incidence of SAEs (serious adverse events)(15 days)
- Change in tooth discoloration index from Visit 1 to Visit 2(baseline and after 5 days of treatment)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5Inhibition of Plaque Formation (by Gingivitis-Index ≤1.5)NCT03322124Schülke & Mayr GmbH100
已完成
不适用
Assessing the Efficacy of a Carbamide Peroxide Mouthwash for Oral Wound Healing, Oral Hygiene and Xerostomia ReliefWound HealOral DrynessPostoperative PainBiopsy WoundSjogren's SyndromeMouth DrynessDental PlaqueGingival InflammationWound MouthNCT06363955National and Kapodistrian University of Athens54
已完成
早期 1 期
Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating DisorderSleep-Related Eating DisorderNCT00606411Massachusetts General Hospital34
已完成
2 期
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's DiseaseSialorrhoeaNCT01370811Orient Pharma Co., Ltd.24
终止
不适用
A Trial to Compare Antibacterial vs. Placebo Mouthwash to Reduce the Incidence of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men (MSM) Taking HIV Pre-Exposure Prophylaxis (PrEP)Sexually Transmitted DiseasesNCT03881007Institute of Tropical Medicine, Belgium343